ARIAD Pharmaceuticals
http://dbpedia.org/resource/ARIAD_Pharmaceuticals an entity of type: Thing
ARIAD Pharmaceuticals, Inc. was an American oncology company, now part of Takeda Oncology, which was founded in 1991 by Harvey J. Berger, M.D. and headquartered in Cambridge, Massachusetts. ARIAD engaged in the discovery, development, and commercialization of medicines for cancer patients. In January 2017, Takeda announced it would acquire ARIAD for $5.2 billion, expanding the company's oncology and hematology business. On February 16, 2017, Takeda Pharmaceuticals, Ltd. announced it had completed its acquisition of ARIAD and incorporated ARIAD into Takeda Oncology.
rdf:langString
rdf:langString
ARIAD Pharmaceuticals
rdf:langString
ARIAD Pharmaceuticals, Inc.
rdf:langString
ARIAD Pharmaceuticals, Inc.
xsd:integer
20737471
xsd:integer
1041883146
<usDollar>
5.4669E8
rdf:langString
Merged with Takeda Pharmaceuticals
xsd:integer
1991
rdf:langString
Chairman of the Board
rdf:langString
President of Research and Development and Chief Scientific Officer
rdf:langString
Alex Denner,
rdf:langString
Ed Fitzgerald,
rdf:langString
Founder, chairman, and CEO Emeritus
rdf:langString
Harvey Berger,
rdf:langString
Marty Duvall,
rdf:langString
Timothy P. Clackson,
rdf:langString
ARIAD logo.png
xsd:integer
151
rdf:langString
US$ million
xsd:integer
380
rdf:langString
US$ million
rdf:langString
AP32788
rdf:langString
Rimiducid
<usDollar>
1.188E8
rdf:langString
NASDAQ:ARIA
rdf:langString
ARIAD Pharmaceuticals, Inc. was an American oncology company, now part of Takeda Oncology, which was founded in 1991 by Harvey J. Berger, M.D. and headquartered in Cambridge, Massachusetts. ARIAD engaged in the discovery, development, and commercialization of medicines for cancer patients. ARIAD’s most prominent drug discoveries include Iclusig, designed for patients with all forms of Philadelphia chromosome-positive [Ph+] chronic myeloid leukemia (CML) or Ph+ acute lymphoblastic leukemia (ALL) who are resistant to or unable to tolerate other tyrosine kinase inhibitors, and brigatinib, a lung cancer drug which has completed its registration trial in ALK fusion driven non-small cell lung cancer as of June 2016 and was approved in the U.S. in April 2017. In January 2017, Takeda announced it would acquire ARIAD for $5.2 billion, expanding the company's oncology and hematology business. On February 16, 2017, Takeda Pharmaceuticals, Ltd. announced it had completed its acquisition of ARIAD and incorporated ARIAD into Takeda Oncology.
xsd:nonNegativeInteger
16193
<usDollar>
5.4669E8
rdf:langString
Merged withTakeda Pharmaceuticals
xsd:gYear
1991
xsd:nonNegativeInteger
380
<usDollar>
1.188E8